XML 73 R51.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Collaboration and Other Agreements, Pfizer (Details) | 1 Months Ended | 12 Months Ended
--- | --- | ---
Oct. 31, 2010 USD ($) | Dec. 31, 2015 USD ($) Molecule Program | Dec. 31, 2014 USD ($) | Dec. 31, 2013 USD ($)
Collaboration and Other Agreements [Line Items] |  |  |  |
Deferred revenue included in current liabilities |  | $ 5,866,000 | $ 14,248,000 |
Pfizer [Member] |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |
Collaboration agreement date |  | October 2010 |  |
Period of agreement |  | 3 years |  |
Commercialization of molecules | Molecule |  | 2 |  |
Nonrefundable upfront payment | $ 5,000,000 |  |  |
DART program | Program |  | 1 |  |
Research obligation completion date |  | January 2014 |  |
Term of the agreement |  | January 2014 |  |
Recognized revenue under agreement |  | $ 500,000 | 100,000 | $ 3,500,000
Milestone achieved |  | 500,000 |  |
Deferred revenue included in current liabilities |  | 0 | $ 0 |
Potential Pre-clinical and Clinical Milestone Payments Under Agreement |  | 17,000,000 |  |
Potential Sales Milestone Payments Under Agreement |  | $ 195,000,000 |  |

X
- Definition Date on which the Company entered into agreement. + References No definition available. + Details
Name: | mgnx_CollaborationAndOtherAgreementEnteredDate
Namespace Prefix: | mgnx_
Data Type: | invest:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Refers to collaborative agreement period of contract. + References No definition available. + Details
Name: | mgnx_CollaborativeAgreementPeriodOfContract
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial fee received from collaboration or license agreement. + References No definition available. + Details
Name: | mgnx_NonRefundableUpfrontFees
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of molecules to be developed and commercialized as per collaboration. + References No definition available. + Details
Name: | mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of programs. + References No definition available. + Details
Name: | mgnx_NumberOfPrograms
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total potential pre-clinical and clinical milestone payments company could earn under agreement + References No definition available. + Details
Name: | mgnx_PotentialPreClinicalAndClinicalMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total potential sales milestones company could earn under agreement + References No definition available. + Details
Name: | mgnx_PotentialSalesMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Refers to research obligation completion date. + References No definition available. + Details
Name: | mgnx_ResearchObligationCompletionDate
Namespace Prefix: | mgnx_
Data Type: | invest:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront fee and participation recognition end date. + References No definition available. + Details
Name: | mgnx_UpfrontFeeAndParticipationRecognitionEndDate
Namespace Prefix: | mgnx_
Data Type: | invest:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |